175 related articles for article (PubMed ID: 33238630)
1. Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1.
Chen H; Afrin S; Guo Y; Chu W; Benzinger TLS; Rogers BE; Garbow JR; Perlmutter JS; Zhou D; Xu J
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238630
[TBL] [Abstract][Full Text] [Related]
2. MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling.
Zhan D; Zhang X; Li J; Ding X; Cui Y; Jia J
Cancer Biother Radiopharm; 2020 Apr; 35(3):223-232. PubMed ID: 32077746
[No Abstract] [Full Text] [Related]
3. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
Shi XL; Li Y; Zhao LM; Su LW; Ding G
Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
[TBL] [Abstract][Full Text] [Related]
4. Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma.
Li X; Li L; Huang Y; Liu B; Chi H; Shi L; Zhang W; Li G; Niu Y; Zhu X
Biomater Sci; 2017 Sep; 5(10):2068-2078. PubMed ID: 28744533
[TBL] [Abstract][Full Text] [Related]
5. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
Gad H; Koolmeister T; Jemth AS; Eshtad S; Jacques SA; Ström CE; Svensson LM; Schultz N; Lundbäck T; Einarsdottir BO; Saleh A; Göktürk C; Baranczewski P; Svensson R; Berntsson RP; Gustafsson R; Strömberg K; Sanjiv K; Jacques-Cordonnier MC; Desroses M; Gustavsson AL; Olofsson R; Johansson F; Homan EJ; Loseva O; Bräutigam L; Johansson L; Höglund A; Hagenkort A; Pham T; Altun M; Gaugaz FZ; Vikingsson S; Evers B; Henriksson M; Vallin KS; Wallner OA; Hammarström LG; Wiita E; Almlöf I; Kalderén C; Axelsson H; Djureinovic T; Puigvert JC; Häggblad M; Jeppsson F; Martens U; Lundin C; Lundgren B; Granelli I; Jensen AJ; Artursson P; Nilsson JA; Stenmark P; Scobie M; Berglund UW; Helleday T
Nature; 2014 Apr; 508(7495):215-21. PubMed ID: 24695224
[TBL] [Abstract][Full Text] [Related]
6. Potent and specific MTH1 inhibitors targeting gastric cancer.
Zhou W; Ma L; Yang J; Qiao H; Li L; Guo Q; Ma J; Zhao L; Wang J; Jiang G; Wan X; Adam Goscinski M; Ding L; Zheng Y; Li W; Liu H; Suo Z; Zhao W
Cell Death Dis; 2019 Jun; 10(6):434. PubMed ID: 31164636
[TBL] [Abstract][Full Text] [Related]
7. Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma.
Huang X; Chen J; Wu W; Yang W; Zhong B; Qing X; Shao Z
Acta Biomater; 2020 Jun; 109():229-243. PubMed ID: 32294550
[TBL] [Abstract][Full Text] [Related]
8. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.
Kawamura T; Kawatani M; Muroi M; Kondoh Y; Futamura Y; Aono H; Tanaka M; Honda K; Osada H
Sci Rep; 2016 May; 6():26521. PubMed ID: 27210421
[TBL] [Abstract][Full Text] [Related]
9. Understanding the molecular mechanism for the differential inhibitory activities of compounds against MTH1.
Wang M; Zhou S; Chen Q; Wang L; Liang Z; Wang J
Sci Rep; 2017 Jan; 7():40557. PubMed ID: 28074893
[TBL] [Abstract][Full Text] [Related]
10. Validation and development of MTH1 inhibitors for treatment of cancer.
Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
[TBL] [Abstract][Full Text] [Related]
11. Biological characterisation and application of human MTH1 and monoclonal antibody preparation.
Chen C; Li X; Gu M; Di R; Kang N; Wang L; Lai Y; Liu Y; Ji X
Oncol Rep; 2019 Mar; 41(3):1851-1862. PubMed ID: 30569141
[TBL] [Abstract][Full Text] [Related]
12. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
Huber KV; Salah E; Radic B; Gridling M; Elkins JM; Stukalov A; Jemth AS; Göktürk C; Sanjiv K; Strömberg K; Pham T; Berglund UW; Colinge J; Bennett KL; Loizou JI; Helleday T; Knapp S; Superti-Furga G
Nature; 2014 Apr; 508(7495):222-7. PubMed ID: 24695225
[TBL] [Abstract][Full Text] [Related]
13. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
[TBL] [Abstract][Full Text] [Related]
14. Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.
Ellermann M; Eheim A; Rahm F; Viklund J; Guenther J; Andersson M; Ericsson U; Forsblom R; Ginman T; Lindström J; Silvander C; Trésaugues L; Giese A; Bunse S; Neuhaus R; Weiske J; Quanz M; Glasauer A; Nowak-Reppel K; Bader B; Irlbacher H; Meyer H; Queisser N; Bauser M; Haegebarth A; Gorjánácz M
ACS Chem Biol; 2017 Aug; 12(8):1986-1992. PubMed ID: 28679043
[TBL] [Abstract][Full Text] [Related]
15. Augment of Oxidative Damage with Enhanced Photodynamic Process and MTH1 Inhibition for Tumor Therapy.
Hu JJ; Chen Y; Li ZH; Peng SY; Sun Y; Zhang XZ
Nano Lett; 2019 Aug; 19(8):5568-5576. PubMed ID: 31262183
[TBL] [Abstract][Full Text] [Related]
16. AuNP flares-capped mesoporous silica nanoplatform for MTH1 detection and inhibition.
Gao W; Cao W; Sun Y; Wei X; Xu K; Zhang H; Tang B
Biomaterials; 2015 Nov; 69():212-21. PubMed ID: 26298289
[TBL] [Abstract][Full Text] [Related]
17. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1.
Dai X; Guo G; Zou P; Cui R; Chen W; Chen X; Yin C; He W; Vinothkumar R; Yang F; Zhang X; Liang G
J Exp Clin Cancer Res; 2017 Sep; 36(1):120. PubMed ID: 28882182
[TBL] [Abstract][Full Text] [Related]
18. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
Pompsch M; Vogel J; Classen F; Kranz P; Iliakis G; Riffkin H; Brockmeier U; Metzen E
BMC Cancer; 2018 Nov; 18(1):1190. PubMed ID: 30497423
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
Peng C; Li YH; Yu CW; Cheng ZH; Liu JR; Hsu JL; Hsin LW; Huang CT; Juan HF; Chern JW; Cheng YS
Bioorg Chem; 2021 May; 110():104813. PubMed ID: 33774493
[TBL] [Abstract][Full Text] [Related]
20. The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors.
Samaranayake GJ; Troccoli CI; Zhang L; Huynh M; Jayaraj CJ; Ji D; McPherson L; Onishi Y; Nguyen DM; Robbins DJ; Karbaschi M; Cooke MS; Barrientos A; Kool ET; Rai P
Mol Cancer Ther; 2020 Feb; 19(2):432-446. PubMed ID: 31744893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]